Abstract 113P
Background
Tumor tissue preservation methods affect proteome profiles differently. To date, no studies have reported a deep proteome comparison of four tissue preservation methods and their corresponding proteome profiles. This study sought to assess the effect of different preservation methods on quantitative proteomics of human breast adjacent normal (NC) and tumor tissues (TC) preserved in Allprotect, snap-frozen by LN2, RNAlater, and formalin solution embedded in paraffin (FFPE).
Methods
Around 7 patients’ TC and NC were preserved in four different storage conditions, which include Allprotect, LN2, RNAlater, and FFPE. A comprehensive deep proteomics analysis using mass spectrometry has been performed to evaluate the effect of storage conditions on the preservation of proteins. Protein yield and coverage were compared in four storage conditions to determine the optimum storage conditions for tissue samples to perform proteomics analysis. Unique proteins obtained from each condition were further analyzed to examine the effect of storage conditions on subcellular location. Differential analysis was performed on all individual conditions to compare the unique statistically differentially expressed proteins.
Results
TC tissues showed the highest protein yield compared to NC because the fat portion was higher in NC. The FFPE condition, followed by RNAlater, was determined to have the maximum protein coverage. Unique proteins could be detected from FFPE samples, providing a hint of the modifications induced during the paraffinization. However, the differential analysis showed more unique proteins in the Allprotect storage conditions, followed by RNAlater. The proteins CNDP2 and PLIN4 showed dysregulation in the TC sample despite the different storage conditions and may be used as therapeutic markers for breast cancer. Biological pathway analysis showed spliceosome and PPAR signaling pathways were enriched in TC compared to NC tissue.
Conclusions
This study evaluated the effects of different tissue preservation methods on proteomics analysis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
IIT Bombay.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
125P - Combination of navitoclax with alpelisib and trametinib to synergistically impair cell viability in high-grade ovarian cancer
Presenter: Lisa Wozelka-Oltjan
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Effect of sequential antitumoral treatment with immune checkpoint blockade and tyrosine kinase inhibitors in hepatocellular carcinoma
Presenter: Vincenza Ciaramella
Session: Cocktail & Poster Display session
Resources:
Abstract
127P - Novel bone-targeting of activatable sirolimus for targeted therapy of bone-resident cancers
Presenter: Alistare Sadra
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Network medicine approach identifies small molecule drugs as immune checkpoint inhibitors repurposable for rectal cancer
Presenter: Faheem Ahmed
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - Repurposing existing therapies for adrenal cancer: Unlocking new possibilities
Presenter: Anupama Samantasinghar
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Restoration of the mutant p53 protein upon treatment with small molecule modulators
Presenter: Elvina Gilyazova
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Trop 2 and its overexpression in metastatic colorectal cancer patients (mCRCp): Biological, clinical and therapeutic implications
Presenter: Andrea Mancuso Petricca
Session: Cocktail & Poster Display session
Resources:
Abstract
132P - Novel small molecule modulators for activation of mutant tumor suppressor p53
Presenter: Damir Davletshin
Session: Cocktail & Poster Display session
Resources:
Abstract
133P - Cytotoxic efficacy of artificial vesicles obtained from CAR-T cells by ultrasonication
Presenter: Ekaterina Zmievskaya
Session: Cocktail & Poster Display session
Resources:
Abstract
134P - Doxorubicin and olaparib (OLA) synergism in high-grade serous ovarian (HGOC) and triple-negative breast cancer (TNBC) cell lines with olaparib-resistance
Presenter: Jose Alejandro Perez Fidalgo
Session: Cocktail & Poster Display session
Resources:
Abstract